MedTrace Logo

Comparing Efficacy and Safety of Inhaled SNG001 to Placebo

NCT01126177 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2012-02-13

No results posted yet for this study

Summary

When people with asthma get respiratory virus such as a cold or flu it often increases asthma symptoms. The investigators will test the study medication to find out if it can prevent the virus spreading from the nose to the lungs.

SNG001 contains Interferon-beta that occurs naturally in the body. In this study, SNG001 will be given by a nebuliser.

Conditions

Interventions

DRUG

Interferon beta 1a

SNG001, IFN-β1a solution for inhalation

DRUG

Placebo

Placebo (excipients of the SNG001 solution only)

Sponsors & Collaborators

  • Synairgen Research Ltd.

    lead INDUSTRY

Principal Investigators

  • Ratko Djukanovic, MD, DM, FRCP · University of Southampton

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-10-31
Completion
2012-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01126177 on ClinicalTrials.gov